These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26266632)

  • 1. Antiplatelet therapy in Takotsubo cardiomyopathy: does it improve cardiovascular outcomes during index event?
    Dias A; Franco E; Koshkelashvili N; Bhalla V; Pressman GS; Hebert K; Figueredo VM
    Heart Vessels; 2016 Aug; 31(8):1285-90. PubMed ID: 26266632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and predictors of stroke during the index event in an ethnically diverse Takotsubo cardiomyopathy population.
    Dias A; Franco E; Janzer S; Koshkelashvili N; Bhalla V; Rubio M; Amanullah S; Hebert K; Figueredo VM
    Funct Neurol; 2016; 31(3):157-62. PubMed ID: 27678209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity.
    Tziomalos K; Giampatzis V; Bouziana SD; Spanou M; Kostaki S; Papadopoulou M; Angelopoulou SM; Tsopozidi M; Savopoulos C; Hatzitolios AI
    Cerebrovasc Dis; 2016; 41(5-6):226-32. PubMed ID: 26795462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting.
    Gasparovic H; Petricevic M; Kopjar T; Djuric Z; Svetina L; Biocina B
    Am J Cardiol; 2014 May; 113(10):1660-7. PubMed ID: 24666617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial.
    Lee H; Koo BK; Park KW; Shin ES; Lim SW; Rha SW; Bae JW; Jeon DW; Oh SK; Hur SH; Kim BS; Lee JH; Park TH; Lee NH; Kim HS;
    Am Heart J; 2017 Mar; 185():17-25. PubMed ID: 28267471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents.
    Park TK; Song YB; Ahn J; Carriere KC; Hahn JY; Yang JH; Choi SH; Choi JH; Lee SH; Gwon HC
    Circ Cardiovasc Interv; 2016 Jan; 9(1):e002816. PubMed ID: 26755571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation.
    Li Q; Ren X; Yu X; He J; Gao Y; Zhang X; Wu C; Luo Y; Zhang Y; Chen F
    Cardiovasc Ther; 2016 Jun; 34(3):127-37. PubMed ID: 26826703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry.
    Schiele F; Puymirat E; Bonello L; Dentan G; Meneveau N; Collet JP; Motreff P; Ravan R; Leclercq F; Ennezat PV; Ferrières J; Berard L; Simon T; Danchin N
    Int J Cardiol; 2015; 187():354-60. PubMed ID: 25839641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
    Manchuelle A; Delhaye C; Schurtz G; Sudre A; Hurt C; Bonello L; Puymirat E; Bauters C; Lemesle G
    Arch Cardiovasc Dis; 2015 Apr; 108(4):235-43. PubMed ID: 25682548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
    Varenhorst C; Jensevik K; Jernberg T; Sundström A; Hasvold P; Held C; Lagerqvist B; James S
    Eur Heart J; 2014 Apr; 35(15):969-78. PubMed ID: 24122961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    Toyoda K; Uchiyama S; Hoshino H; Kimura K; Origasa H; Naritomi H; Minematsu K; Yamaguchi T;
    Int J Stroke; 2015 Feb; 10(2):253-8. PubMed ID: 25487817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.
    Siller-Matula JM; Delle-Karth G; Christ G; Neunteufl T; Maurer G; Huber K; Tolios A; Drucker C; Jilma B
    Int J Cardiol; 2013 Jul; 167(2):430-5. PubMed ID: 22305813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
    Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
    Campo G; Tebaldi M; Vranckx P; Biscaglia S; Tumscitz C; Ferrari R; Valgimigli M
    J Am Coll Cardiol; 2014 Feb; 63(6):506-12. PubMed ID: 24161321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation.
    Ussia GP; Scarabelli M; Mulè M; Barbanti M; Sarkar K; Cammalleri V; Immè S; Aruta P; Pistritto AM; Gulino S; Deste W; Capodanno D; Tamburino C
    Am J Cardiol; 2011 Dec; 108(12):1772-6. PubMed ID: 21907949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.